Screener
Theravance Biopharma TBPH Compensation and benefits
Discontinued — last reported Q2 '23
Compensation and benefits at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Theravance Biopharma’s 10-Q, filed August 9, 2023.
- Filed
- Aug 9, 2023
- Fiscal quarter
- Q2 FY2023
- Calendar quarter
- Q2 2023
- Accession
- 0001558370-23-014070
| (In thousands) | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 |
|---|---|---|---|---|
| Research and development | $1,855 | $2,909 | $4,296 | $7,439 |
| Selling, general and administrative | 4,409 | 5,030 | 8,632 | 10,528 |
| Restructuring and related expenses | — | 1,770 | 357 | 6,287 |
| Total share-based compensation expense | $6,264 | $9,709 | $13,285 | $24,254 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's compensation and benefits?
- Theravance Biopharma (TBPH) reported compensation and benefits of $6.26M in Q2 2023.
- How has Theravance Biopharma's compensation and benefits changed year-over-year?
- Theravance Biopharma's compensation and benefits decreased by 35.5% year-over-year, from $9.71M to $6.26M.
- What does compensation and benefits mean?
- Total employee-related costs including salaries, wages, bonuses, commissions, stock-based compensation, health insurance, retirement contributions, and payroll taxes.
Ask your AI about Theravance Biopharma's compensation and benefits.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude